GSK (LON:GSK) Insider Julie Brown Buys 5 Shares of Stock

GSK plc (LON:GSK) insider Julie Brown bought 5 shares of the stock in a transaction that occurred on Monday, April 13th. The stock was bought at an average cost of GBX 2,171 per share, for a total transaction of £108.55.

Julie Brown also recently made the following trade(s):

• On Tuesday, February 10th, Julie Brown bought 6 shares of GSK stock. The stock was bought at an average cost of GBX 2,179 per share, for a total transaction of £130.74.

GSK Trading Up 0.9%

Shares of GSK opened at GBX 2,190 on Wednesday. The firm’s 50 day simple moving average is GBX 2,110.80 and its 200 day simple moving average is GBX 1,890.47. The company has a market capitalization of £87.53 billion, a P/E ratio of 15.78, a P/E/G ratio of 1.24 and a beta of 0.35. The company has a debt-to-equity ratio of 108.20, a current ratio of 0.82 and a quick ratio of 0.73. GSK plc has a 1-year low of GBX 1,263.50 and a 1-year high of GBX 2,282.

GSK (LON:GSK) last issued its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a net margin of 17.50% and a return on equity of 37.19%. Sell-side analysts forecast that GSK plc will post 175.980975 earnings per share for the current fiscal year.

GSK News Roundup

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Positive Phase I BEHOLD‑1 data for Mo‑Rez in endometrial and ovarian cancer — early results were reported as encouraging, which boosts GSK’s oncology pipeline prospective value and investor sentiment. GSK announces positive outcomes from Phase I BEHOLD-1 trial of Mo-Rez
• Positive Sentiment: Share buyback continued: GSK repurchased 325,000 ordinary shares (13 April), expanding treasury stock and lifting treasury holdings to ~6.36% of voting rights — buybacks reduce float and are a direct capital-return/earnings-per-share support. GSK Expands Treasury Stock with Latest Share Buyback Tranche GSK Expands Share Buyback, Lifts Treasury Holdings to 6.36% of Voting Rights
• Positive Sentiment: Jefferies reaffirmed a “buy” rating with a GBX 2,500 price target — a favorable broker upgrade/confirmation that can attract momentum and institutional interest. Broker Views
• Positive Sentiment: Insiders/executives buying: a disclosed executive share acquisition under GSK’s reward plan and an insider (Julie Brown) bought 5 shares at ~GBX 2,171 — modest but supportive signals that management has some conviction in the stock. GSK Executives Acquire Shares Under Company Reward Plan
• Neutral Sentiment: Overall analyst consensus remains mixed to neutral — an aggregate “Hold” rating was reported from brokerages, indicating some caution despite the positives above. GSK Receives Average Rating of “Hold” from Brokerages

Analyst Upgrades and Downgrades

GSK has been the topic of a number of recent research reports. Shore Capital Group reiterated a “buy” rating on shares of GSK in a research report on Wednesday, March 25th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research report on Wednesday, January 7th. Berenberg Bank reiterated a “hold” rating and set a GBX 2,000 price target on shares of GSK in a research report on Thursday, March 26th. Deutsche Bank Aktiengesellschaft increased their price target on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a research report on Thursday, January 15th. Finally, Jefferies Financial Group restated a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a report on Tuesday. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of GBX 2,023.57.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.